Quetiapine in adolescents with psychosis: a 12 weeks open label trial
Détails
ID Serval
serval:BIB_08A52DBB190A
Type
Actes de conférence (partie): contribution originale à la littérature scientifique, publiée à l'occasion de conférences scientifiques, dans un ouvrage de compte-rendu (proceedings), ou dans l'édition spéciale d'un journal reconnu (conference proceedings).
Sous-type
Abstract (résumé de présentation): article court qui reprend les éléments essentiels présentés à l'occasion d'une conférence scientifique dans un poster ou lors d'une intervention orale.
Collection
Publications
Institution
Titre
Quetiapine in adolescents with psychosis: a 12 weeks open label trial
Titre de la conférence
Schizophrenia Research
ISBN
0920-9964
Statut éditorial
Publié
Date de publication
2008
Peer-reviewed
Oui
Volume
98
Série
Schizophrenia Research
Pages
162
Langue
anglais
Notes
SAPHIRID:68311
Résumé
Background: Clinical effectiveness, tolerability and pharmacokinetics of quetiapine in adolescents with psychotic disorders have been established, but cognitive functions have not yet been examined specifically in this population.
Methods: We assessed 23 adolescents (13-18 years old) with psychotic disorders participated in a 12-week open-label trial assessing clinical efficacy, tolerability and impact on cognitive functions of quetiapine (50-750 mg daily).
Results: Adolescents were treated with lower doses compared to adults, a decrease in Clinical Global Impression (CGI) and Positive and Negative Syndrome Scale (PANSS) total score was observed while neuropsychological functioning remained stable after 12 weeks of quetiapine treatment.
Conclusions: Quetiapine is an effective and well tolerated treatment in adolescents with psychotic disorders, no improvement in cognitive functioning has been observed in this trial.
Methods: We assessed 23 adolescents (13-18 years old) with psychotic disorders participated in a 12-week open-label trial assessing clinical efficacy, tolerability and impact on cognitive functions of quetiapine (50-750 mg daily).
Results: Adolescents were treated with lower doses compared to adults, a decrease in Clinical Global Impression (CGI) and Positive and Negative Syndrome Scale (PANSS) total score was observed while neuropsychological functioning remained stable after 12 weeks of quetiapine treatment.
Conclusions: Quetiapine is an effective and well tolerated treatment in adolescents with psychotic disorders, no improvement in cognitive functioning has been observed in this trial.
Création de la notice
23/06/2008 15:01
Dernière modification de la notice
20/08/2019 12:30
Données d'usage
